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HIV-1 ENTRY IN RENAL TUBULE EPITHELIAL CELLS THROUGH HSPG-
DEPENDENT UPTAKE PATHWAYS 
NAUSHIN S. ALI 
ABSTRACT 
Human immunodeficiency virus (HIV) targets and depletes CD4+ T cells, 
compromising the body’s ability to fight off infections. Progressed HIV disease can lead 
to impaired renal function known as HIV-associated nephropathy (HIVAN). Epithelial 
cells are typically ineffective targets of HIV-1 as they lack the CD4 and CCR5 molecules 
that are involved in viral entry into CD4+ T cells. However, previous research in the 
laboratory of Dr. Benjamin K. Chen demonstrated that renal tubule epithelial (RTE) cells 
were capable of viral uptake through a T cell-mediated, but CD4-independent 
mechanism. In addition, experiments implicated heparan sulfate proteoglycans (HSPG) 
as possible attachment receptors for HIV-1 through their heparan sulfate (HS) 
polysaccharide chains. The addition of anti-HSPG and anti-syndecan 1 antibodies 
blocked virus transfer by approximately 50%, suggesting a role for HSPG in viral entry. 
As a result, the syndecan (SDC) class of heparan sulfate receptors were assessed for their 
potential to serve as attachment receptors for HIV-1 through knockout studies. A co-
culture system with donor HIV-expressing Jurkat T cells and target renal tubular 
epithelial (HK2) cells were used as a system for HIVAN pathogenesis and enabled cell-
to-cell viral transfer. Despite the generation of stable SDC gene knockout lines, no 
change in viral transfer was observed, suggesting redundant or alternate pathways for 
HIV-1 entry. Understanding viral entry into epithelial cells is crucial as these sites can 
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serve as reservoirs for HIV-1, where it can continue to replicate even when plasma viral 
load has been sufficiently reduced with antiretroviral treatment.  
		 vii 
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INTRODUCTION 
 
There are approximately 37 million individuals currently living with human 
immunodeficiency virus (HIV) worldwide [1-3]. Almost three-quarters of HIV-infected 
individuals reside in sub-Saharan Africa, where there is a higher prevalence of infection 
compared to the United States (US) [1, 3]. While the global rate of new HIV infection has 
decreased by 38% since 2001 [3], there were 2 million new cases of HIV infections that 
occurred in 2015 [1-3]. Currently, it is estimated that there are 1.2 million HIV-positive 
individuals in the United States, where the annual incidence has remained stable over the 
past decade at ~50,000 cases per year [1, 3]. Today, HIV infection can be described as a 
chronic illness with the advent of antiretroviral therapy, which suppresses viral 
replication [1].  
 
HIV-Associated Nephropathy 
Shortly after the HIV epidemic began in the early 1980s, renal dysfunction was 
recognized as a possible complication of progressed HIV disease [1, 3, 4]. In 1984, a 
landmark paper by Rao et al investigated the prevalence of kidney disease among HIV-
infected individuals in the US [5]. They described the first cases of what is now known as 
HIV-associated nephropathy (HIVAN), which affects all renal compartments including 
the interstitium, glomeruli and tubules. Local HIV infection of the kidney preludes the 
diagnosis of HIVAN, with the virus infecting podocytes as well as tubular- and 
glomerular epithelial cells.  
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Clinically, HIVAN presents with proteinuria, impaired renal function and 
occasionally edema [1, 3]. Some patients may also be edematous due to malnutrition 
and/or salt wasting caused by renal tubular injury. Histologically, HIVAN is described as 
a distinct form of collapsing focal segmental glomerulosclerosis (FSGS). As expected, 
FSGS is characterized by segmental scarring of the glomeruli. Additional histological 
markers include interstitial inflammation, fibrosis, and microcystic renal tubular 
dilatation [1]. 
 Before the introduction of combined antiretroviral therapy (cART), about 3-10% 
of HIV-infected individuals in the US were diagnosed with HIVAN [1]. Following 
widespread use of cART, the incidence of HIVAN has since decreased [1]. In the absence 
of cART, HIVAN rapidly progresses to end-stage renal disease (ESRD), causing 
significant kidney impairment that necessitates dialysis and eventually kidney transplant 
[1]. Given that patients having increasingly longer life expectancies with cART, the 
prevalence of ESRD continues to increase [1, 4]. 
 
Risk Factors 
 While the rates of HIVAN vary across the globe, the region with the highest 
prevalence is sub-Saharan Africa [1, 2, 4]. In the United States, HIVAN occurs more 
commonly in those of African descent, which can be partially attributed to genetic 
susceptibility [1, 4]. The onset of HIVAN in a given individual can further be illuminated 
by the interactions among pathogen, host, environmental and behavioral attributes [1], 
summarized in Figure 1. Specifically, environmental and behavioral factors include 
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access to and compliance with standard of care treatments including cART. Pathogen 
factors can include the variability in viral protein expression in the kidney. Host factors 
are in part characterized by genetic predispositions that largely affect patients of African 
descent [1, 4].  
One such gene involved is APOL1 which encodes apolipoprotein L1, a protein 
component of certain high-density lipoproteins that make up two types of trypanosome 
lytic factor, which confers protection against Trypanosoma brucei, the parasite that 
causes African sleeping sickness [1, 4]. Specific variants of APOL1 have been shown to 
be strongly associated with HIVAN and are exclusively found in patients of African 
heritage, suggesting a positive selection. It is proposed that these “risk” alleles may 
confer an advantage through increased trypanolytic activity, not unlike the selective 
advantage of sickle-cell heterozygosity in regions where malaria is prevalent [1, 4]. 
Another gene enriched in African-American populations that has been strongly 
associated with HIV-associated FSGS in addition to idiopathic FSGS is MHY9, which 
codes for non-muscle myosin heavy chain IIA [4]. However, it is suggested that 
additional genetic and/or environmental factors are necessary to confer an increased risk 
of HIVAN [4]. 
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Figure 1: Interactions of various factors contributing to HIVAN, adapted from 
Cohen et al, 2017. 
 
The Kidney as a Viral Reservoir 
 The pathogenesis of HIVAN was first described in 2000, when Bruggeman et al 
detected HIV-1 in renal tubule epithelial cells and glomerular podocytes, identifying a 
connection between HIV-1 and renal tissue [6]. They reported evidence that three of the 
four patients studied who had undetectable viral loads in circulation continued to have 
viral replication in renal compartments even on cART, suggesting the kidney may be a 
viral reservoir. In situ hybridization experiments performed on human kidney tissue 
showed the presence of both spliced and unspliced viral mRNA in these renal 
compartments. 
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Further evidence that the kidney could support viral infection was in a report by 
Winston et al who detected viral RNA intracellular expression in both the presence and 
absence of cART [7]. DNA extracted from renal biopsies before and after cART had 
clearly demonstrated that treatment had blocked further infection of kidney cells through 
the lack of the circular form of viral DNA containing long-terminal repeats, which are 
considered to be indicative of recent infection. 
Elegant phylogenetic analyses of two patient kidney biopsies showed that HIV-1 
viral variants from renal tubules clustered separately from those coming from PBMCs 
from each patient [8]. The discovery of unique renal viral variants was strongly 
suggestive that the kidney may serve as an independent site of replication. 
 Canaud et al assessed biopsies from HIV patients who underwent kidney 
transplants and found that both viral RNA and DNA were still present in podocytes and 
renal tubule epithelial cells [9]. This further strengthened the idea that viral replication 
continues in renal tissue despite systemic virological suppression on cART. 
 In 2014, Blasi et al were the first to demonstrate productive HIV-1 infection of 
renal tubule epithelial cells using immortalized and primary cell lines [10]. That is, 
following viral transfer to renal cells, HIV-1 was reverse-transcribed and integrated into 
the target genome. These infected renal cells were able to produce new virus particles and 
transfer them back to T cells in a contact-dependent manner. These findings, along with 
those described earlier, supported the notion that the kidney acts as an HIV-1 reservoir. 
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Cell-to-Cell HIV Transmission 
The first study to explore entry mechanisms into epithelial cells found that under 
in vitro conditions, cell-to-cell infection mediated by T cells was significantly more 
efficient that transmission through cell-free virus [11]. The presence of infiltrating T cells 
in kidney biopsies of HIVAN patients further supported the notion that T lymphocytes 
may play a direct role in transferring HIV-1 to renal tissue [6].  
The two typical pathways that are known to facilitate viral entry, via membrane 
fusion or endocytosis into a cell, are both receptor-mediated. Yet epithelial cells lack the 
CD4 and CCR5 receptors that are classically involved in viral entry into CD4+ T cells, 
which would suggest that they are ineffective targets [10, 11]. This led to a search by 
several investigators for molecules that mediate HIV-1 entry into renal epithelial cells. 
While one study found that the C-type lectin receptor, DEC-205, appeared to facilitate T-
cell dependent HIV-1 entry into the immortalized renal tubule epithelial cell line HK2, 
there was no evidence of a productive infection [12]. 
Recently, an in vitro system co-culture system was used by Chen et al to further 
characterize cell-to-cell HIV-1 transfer [13]. Briefly, HIV-infected Jurkat T cells were 
co-cultured with uninfected HK2 cells and found to produce a more robust infection than 
cell-free virus infection of HK2 cells. This viral entry mechanism was determined to be 
CD4- and Env-independent. Furthermore, chemical inhibitors of heparan sulfate 
proteoglycans (HSPGs) as well as monoclonal antibodies targeting HSPG, Syndecan-1 
and agrin all showed a significant reduction (~50%) in cell-to-cell virus transfer. Given 
that heparan sulfates have been known to play a role in cell adhesion, it was hypothesized 
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that the inhibitors used may affect cell-cell contact and suggest a specific role of these 
molecule subtypes in HIV-1 entry in renal epithelial cells. 
Other groups have also found HSPG involvement in HIV-1 transmission from T 
cells to intestinal epithelial cells (HT29), which further support nonconventional cell 
surface HIV-1 entry pathways through what Alfsen et al termed a “viral synapse” [14]. 
Heparan Sulfate Proteoglycans 
HSPGs comprise a large class of proteins that contain HS glycosaminoglycan 
(GAG) polysaccharide chains [15]. Heparan sulfates are conjugated to different types of 
proteins that each have preferential localizations. For example, perlecan is distributed on 
the extracellular matrix, and both glipicans and syndecans are associated with the cell 
surface. The canonical model of the role of HSPGs in endocytosis had long described 
ligand binding to HSPG that resulted in a ligand-specific conformational change which 
enabled ligand presentation to endocytic receptors. Endocytosis further can be divided 
into clathrin- dependent and independent internalization; both pathways may be used in 
SDC- and glipican-mediated entry.  
Syndecans (SDCs) are a type I transmembrane HSPG that have an extended 
extracellular domain that contains three heparan sulfate chains [15, 16]. Syndecans 
interact with ligands through the sulfated regions of the HS chains and the basic amino 
acid residues on the ligand’s surface. There are 4 members of the SDC family: SDC-1, 
SDC-2, SDC-3, and SDC-4. While the former has been shown to be the primary 
syndecan expressed on epithelial surfaces, the other three have still been shown to be 
expressed at varying levels depending on tissue-type. 
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In one study by Bobardt et al, each syndecan subtype was introduced to B 
lymphocytes that natively lack HIV-1 attachment receptors such as CD4, lectins and 
HSPGs and was shown to facilitate HIV-1 entry [17]. When the heparan sulfate chains 
were enzymatically cleaved, HIV-1 entry was inhibited, signifying that these chains 
contain the HIV-1 binding sites on the target cell.  
 These syndecan subtypes remain to be individually investigated in renal tubule 
epithelial cells for their potential role in viral entry, as suggested by Chen et al [13]. 
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SPECIFIC AIMS 
 
Previous research at the laboratory of Dr. Benjamin K. Chen demonstrated that 
renal tubule epithelial (RTE) cells were capable of viral uptake through a T cell-
mediated, but CD4-independent mechanism [13]. In addition, the studies supported the 
hypothesis that heparan sulfate proteoglycans (HSPGs) can serve as attachment receptors 
for HIV through their heparan sulfate (HS) polysaccharide chains. The addition of anti-
Syndecan 1 antibodies blocked virus transfer by approximately 50%, suggesting a role 
for the syndecan family in viral entry. 
Understanding viral entry into epithelial cells is crucial as these sites can serve as 
reservoirs for HIV, where it can continue to replicate even when plasma viral load has 
been sufficiently reduced with antiretroviral treatment. 
The goal of this study was to use inhibition assays to assess HIV-1 entry in renal 
tubule epithelial cells through cell-to-cell transfer. CRISPR/Cas9 gene editing technology 
was used to knock out and to assess importance of the syndecan (SDC) family as 
attachment receptors in viral transfer. 
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METHODS 
 
Cells and Tissue Culture 
  The human renal proximal epithelial cell line HK-2 and CD4+ Jurkat T-cell line 
were obtained from American Type Culture Collection. Jurkat cells were maintained in 
RPMI 1640 (Gibco), with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% fetal 
bovine serum (FBS). Cells were passaged and maintained at a density of <5 × 105 
cells/mL. HK-2 cells were cultured in Keratinocyte-SFM (Invitrogen) supplemented with 
2.5 mg/mL bovine pituitary extract and 0.25 g/mL recombinant EGF. The lentivirus-
packaging cell line 293T (ATCC) was cultured in DMEM (Sigma-Aldrich) supplemented 
with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FBS. 
 
CRISPR Plasmid Construction 
 A lentiCRISPRv2-puromycin plasmid that was previously digested with BsmBI 
was used. Short guide RNAs (sgRNAs) targeting SDC-1, SDC-2, SDC-3, and SDC-4 
genes were developed based on the protocols of Dr. Feng Zhang from MIT [18] and 
chosen based on minimizing off-target effects (Tables 1-4). Each target sequence was 
synthesized as a pair of oligonucleotides, treated with T4 polynucleotide kinase and then 
annealed in T4 DNA ligation buffer. The double-stranded oligos were diluted 1:100 and 
incubated with the lentiCRISPRv2-puromycin plasmids to set up a ligation reaction in 
presence of T4 DNA ligase. This mixture was transformed into Stbl2 competent cells 
(Invitrogen) under carbenicilin selection. Plasmids were then isolated by miniprep 
(Qiagen) and verified through DNA Sanger sequencing. 
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Lentivirus Production 
  293T cells were seeded in a 6-well format at 4-8 × 105 cells per well 18-24 hours 
prior to transfection. 30 minutes prior to transfection, 1mL of serum-containing media 
from each well was removed. Each transfection reaction consisted of a PolyJet-DNA 
complex in a 3:1 ratio created in a 96-well plate. The DNA complex was prepared by 
combining 0.5 µg of envelope (VSV-G) plasmid, 1.0 µg of packaging (PAX2) plasmid, 
and 1.5 µg of vector (lentiCRISPRv2-puromycin targeting SDC-1, SDC-2, SDC-3, SDC-
4 or a non-targeting control) plasmid. 293T cells were transfected according to the 
manufacturer’s protocol (SignaGen). At 48 hours post-transfection, viral supernatants 
were harvested (~1.8 mL), filtered through a 0.22 µm filter, and stored in a freezer at -
20°C. 
 
Generation of Stable SDC Knockout Cell Lines 
  HK2 cells were seeded in a 6-well format and grown under normal culture 
conditions until reaching 50-60% confluency. At day 0, cells were then transduced with 
lentiCRISPRv2-puromycin lentiviruses targeting either SDC-1, SDC-2, SDC-3, SDC-4 
or a non-targeting control (scramble). At 24 hours post-transduction (day 1), culture 
dishes were replaced with full media. At 48 hours post-transduction (day 2), cells were 
selected with 2 µg/mL of puromycin for up to two weeks and expanded as needed. The 
knockout efficiency was assessed around day 13 with flow cytometry. 
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Immunofluorescence Staining for Assessment of SDC knockouts 
  HK2 cells were dissociated using a non-enzymatic solution, Versene (Gibco) and 
washed with ice cold phosphate buffered saline (PBS) 1% bovine serum albumin (BSA). 
Cells were then centrifuged and re-suspended at a concentration of 1-5 × 105 cells/mL 
with 100 µL of a solution containing 1% BSA and a 1:500 dilution of an aqua live/dead 
stain (Invitrogen) in PBS. 5 µL of an anti-hSyndecan APC-conjugated antibody specific 
for either SDC-1, SDC-2, SDC-3, or SDC-4 (R&D Systems) were added to each well and 
incubated in the dark for 45 minutes at 4°C. Appropriate isotype controls from R&D 
Systems were also used for each antibody. Cells were then washed 3 times by 
centrifugation at 300 g for 5 minutes and re-suspended in 500 µL of ice cold PBS with 
1% BSA. After the third wash, cells are fixed in 1% paraformaldehyde (PFA) and stored 
at 4°C until analysis by flow cytometry. The measure of SDC expression was assessed 
with FlowJo software. 
 
HIV infection and Nucleofection of Donor T Cells 
  HIV-expressing donor cells were obtained by transfecting Jurkat cells with HIV-1 
proviral constructs (HIV Gag-iGFP) using Amaxa nucleofection (Amaxa Biosystems).  
HIV Gag-iGFP expression was then assessed with flow cytometry. First, 6 µg of HIV-1 
proviral plasmids were nucleofected into 7 × 106 cells by using Amaxa Cell Line 
Nucleofector Kit V and Program S-18. Nucleofected Jurkat cells were enriched 24 hours 
later by centrifugation on a Ficoll density gradient. The enriched cells were cultured for 
an additional 24 hours before being used as donors in transfer experiments. 
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HIV-1 Cell-to-Cell Transfer 
  Jurkat to HK2 HIV-1 transfer was assessed in a co-culture system (Figure 2). The 
target HK2 cells were labelled with 2 µM of CellTracker orange CMTMR fluorescent 
dye (Molecular Probes) for 30 minutes at 37°C and then washed with PBS. The labelled 
HK2 cells were seeded in a 24-well plate at 2.5 × 105 per well and cultured overnight. 
The following day, 1 × 106 donor Jurkat cells were added to the HK2 epithelial 
monolayer, and co-cultured for 4 hours. Termination of co-culture was completed by 
three PBS washes in order to remove Jurkat cells. The adherent HK2 cells were detached 
with 0.05% trypsin-EDTA, washed once, and then fixed with 1% PFA in preparation for 
analysis by flow cytometry. The measure of virus (HIV Gag-iGFP) transfer was assessed 
with FlowJo software. A summary of the experimental design from SDC knockout to 
assessing its relationship with viral transfer can be seen in Figure 3. 
 
 
Figure 2: Co-culture system for assessing viral transfer. 
 
 
Suspension	of	Jurkat	cells	
	
	
Monolayer	of	HK2	cells	
Co-culture	system	
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Figure 3: Summary of experimental design. 
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RESULTS 
Optimization of Jurkat to HK-2 HIV-1 Transfer 
 
In order to maximize the efficiency of HIV-1 introduction into Jurkat cells, 4 
different HIV Gag-iGFP concentrations (4 µg, 6 µg, 8 µg, and 10 µg) were assessed for 
their nucleofection efficiency as well as for cell death (Figure 4). Given that GFP has 
been inserted into this proviral construct, viral particles can be visualized under light 
microscopy (Figure 4b). Virus uptake was assessed with flow cytometry. 
  
 
Figure 4: Nucleofection of Jurkat cells with varying concentrations of HIV Gag-
iGFP for use as donor cells in cell-to-cell transfer studies. a) FACS profile of GFP 
fluorescence in Jurkat cells. b) Jurkat cells examined under light microscopy show 
punctate dots of GFP in the cytoplasm. 
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While the highest transfection occurred with 6 µg of HIV Gag-iGFP at 8.9% of 
the Jurkat cells being infected, the greatest cell survival in the infected populations was 
with 4 µg of Gag-iGFP (Figure 4a). 
 The Jurkat populations transfected with varying HIV Gag-iGFP concentrations 
were then co-cultured with target wild-type HK2 cells to assess virus transfer (Figure 5). 
From the raw data, 6 µg of HIV Gag-iGFP produced the highest transfer to HK2 cells at 
13.3%. However, given the varying degree of cell death associated with Jurkat 
transfection, these transfer values were normalized to the control population to provide a 
more accurate comparison (Figure 6).  
 
Figure 5: Profile of GFP fluorescence in HK2 cells after co-culture with Jurkat cells 
transfected with varying concentrations of HIV Gag-iGFP. 
4 µg DNA	Negative control	 6 µg DNA	
8 µg DNA	 10 µg DNA	 Cell-to-cell	viral	transfer	to	wild-type	HK2	cells		
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Figure 6: Normalized HIV-1 transfer efficiencies from Jurkat cells to HK2 cells. 
Jurkat cells were transfected with varying concentrations of HIV Gag-iGFP before used 
in transfer studies. 
 
Following normalization of GFP expression among the different Jurkat 
populations, 6 µg of HIV Gag-iGFP still presented the highest virus transfer to HK2 cells 
in addition to having the highest transfection efficiency. For all subsequent co-culture 
transfer assays, 6 µg of HIV Gag-iGFP was used to transfect Jurkat cells. 
 
Design of Syndecan-Targeting CRISPR Constructs 
 
 For each Syndecan subtype, 5-6 guide RNAs (gRNAs) were selected and 2 clones 
per target were extracted by miniprep were sequenced to verify construct insertion 
02
46
810
1214
1618
4 6 8 10T
ra
ns
fe
r E
ffi
ci
en
cy
 (%
)
HIV-IGFP (µg)
Normalized Jurkat To HK2 
HIV-1 Transfer Efficiency
	18 
(Tables 1-5). Clones that had a 100% match within the 20 bp gRNA sequence were 
combined. Final concentrations of minipreps ranged from 100-500 ng/µL. 
 
Table 1: 20 base-pair (bp) guide sequences for SDC1. 
Protein	 Target	 gRNA	Sequence	 20	bp	match	(%)	
SDC1	 1	 TACAGCCGTATTCTCCCCCG	 100	
	 2	 GTTCCGGCGGTCAGGCTCCA	 100	
	 3	 CTTCTGGTAGGCCCCGCCGT	 100	
	 4	 ACAGCTCCCGACCACTCATC	 n/a	
	 5	 AGCCGAAACAAGCCAACGGC	 100	
	 6	 CCGGTGGGTTCTGGAGACGT	 100	
	
 For SDC-1, target 4 gRNAs were not successfully inserted (as indicated in Table 
1) into the lentiCRISPRv2-puromycin backbone and were discarded. 
 
Table 2: 20 bp guide sequences for SDC2. 
Protein	 Target	 gRNA	Sequence	 20	bp	match	(%)	
SDC2	 1	 GATGACTACGCTTCTGCGTC	 100	
	 2	 GTTCTGTATATTCAGCGTCG	 100	
	 3	 GCGTAGTCATCGTCATCAAT	 100	
	 4	 TCATGCGATACACCAACAGC	 100	
	 5	 GGTCGAGATGTTGTCAGCTC	 100	
	 6	 TACGCATAAAACTCCTTAGT	 100	
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Table 3: 20 bp guide sequences for SDC3. 
Protein Target gRNA	Sequence 20	bp	match	(%) 
SDC3 1 GTATGTGACGCTCGCCTGCT 100 
 2 TGAGAACTTCGAGAGACCCG 100 
 3 CCGAGCCCGACCCCGAGTAG n/a 
 4 CTCTGGCTCATCCCGGATTG 100 
 5 GCGCCGCCGCCATGAAGCCG 100 
 6 AGCTGAGCTGCCCGAGTCGA 100 
 
 Similarly, target 3 for SDC-3 was also not incorporated in miniprep and 
subsequently excluded from further experiments. 
 
Table 4: 20 bp guide sequences for SDC4. 
Protein Target gRNA	Sequence 20	bp	match	(%) 
SDC4 1 GCTTCACGCGTAGAACTCAT	 100 
 2 CGGAGCCCTACCAGACGATG	 100 
 3 CCCACTACATCCTCATCGTC	 100 
 4 CTCACCCGTTGAAGAGAGTG	 100 
 5 GCGCTGCTGCTGTTCTTCGT	 100 
 
Table 5: 20 bp guide sequences for non-targeting control (scramble). 
Protein Target gRNA	Sequence 20	bp	match	(%) 
Scramble 1 GTATTACTGATATTGGTGGG 100 
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Syndecan-1  
 Compared to the other syndecan subtypes, SDC-1 knockout lines were stable for 
the longest period of time, with expressions remaining low even at 31 days post-
transduction (Figure 7). Targets 1, 2, and 6 had the lowest expression levels compared to 
wild-type and the scramble control.  
 
Figure 7: Percentage of SDC-1 expression in HK-2 cells at day 31 post-transduction. 
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 A transfer assay was carried out 2 days after the SDC-1 staining to assess whether 
the knockout of SDC-1 would affect HIV Gag-iGFP virus transfer from Jurkat cells to 
HK-2 cells. Each condition was run in duplicates (not shown). As seen in Figure 8, no 
apparent change in virus transfer can be discerned between the knockout HK2 lines and 
the control (wild-type and scramble) HK2 populations. 
 
Figure 8: Jurkat to HK-2 HIV-1 transfer in SDC1(-) lines.  
 
 Syndecan expression was further plotted against HIV-1 virus uptake (Figure 9, 
lower panel). While there appears to be an inverse relationship with SDC1 expression and 
virus uptake, these results were not statistically significant. 
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Figure 9: Overview summary of SDC-1 experiments.  
 
Syndecan-2  
 SDC-2(-) lines did not display as robust reductions in target knockouts compared 
to wild-type (Figure 10). Moreover, SDC-2 wild-type expression has been shown to be 
consistently higher than SDC-1 expression (data not shown). 
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 Furthermore, the knockout of SDC-2 was not as strong as SDC-1 knockouts, with 
a maximum of 35.6% reduction in SDC-2 surface expression (Figure 10). Knockouts, 
however, were assessed at later time points and found to show similar expression levels, 
implying that the variations in SDC-2 expression among these conditions are not due to 
stochastic variability (not shown). 
 
Figure 10: Percentage of SDC-2 expression in HK-2 cells at day 16 post-
transduction. 
  
 The HK-2 cell lines with varying SDC-2 expression were then co-cultured with 
infected Jurkat cells to assess differences in virus uptake (Figure 11). While targets 2, 5, 
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and 6 appeared to have similar levels of virus uptake to wild-type and scramble-
controlled HK-2 cells, there appeared to be a slight increase in virus uptake for targets 1, 
2, and 4.  
 
Figure 11: Jurkat to HK-2 HIV-1 transfer in SDC2(-) lines.  
  
 However, when comparing SDC-2 expression directly to virus uptake (Figure 12, 
lower panel), there is no discernable relationship that can be established. 
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Figure 12: Overview summary of SDC-2 experiments.  
 
Syndecan-3 
 At 24 days post-transduction, SDC-3 expression was assessed (Figure 13). Unlike 
the earlier two expression studies, there was a disparity in SDC-3 expression between the 
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wild-type and scramble-controlled HK-2 populations. Despite this significant deviation, a 
reduction in SDC-3 expression may still be concluded for targets 2, 4, 5, and 6. 
 
 
Figure 13: Percentage of SDC-3 expression in HK-2 cells at day 24 post-
transduction. 
 
 When SDC-3(-) HK-2 cells were co-cultured with infected Jurkat cells, there was 
no difference in virus uptake regardless of SDC-3 expression levels (Figure 14). 
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Figure 14: Jurkat to HK-2 HIV-1 transfer in SDC3(-) lines.  
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Figure 15: Overview summary of SDC-3 experiments. 
 
Syndecan-4 
 SDC-4 expression levels in HK2 cells were assessed at 22 days post-transduction 
(Figure 16). Given the variation in SDC-4 expression between the wild-type HK-2 cells 
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and the scramble-controlled population, only targets 2-5 could be reliably concluded to 
produce a significant knockout effect. 
 
Figure 16: Percentage of SDC-4 expression in HK-2 cells at day 22 post-
transduction. 
 
 In the co-culture assay for Jurkat to SDC4(-) HK-2 cells, little virus transfer could 
be seen in wild-type and knockout populations (Figure 17). Reactions have not been run 
with technical replicates or repeated, and so these results do not allow a conclusive 
determination as to whether SDC-4 expression levels affect virus uptake. 
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Figure 17: Jurkat to HK-2 HIV-1 transfer in SDC4(-) lines.  
 
 In this study we observed a poor overall cell-to-cell transfer efficiency, in the 
control cells, however, we still could detect some viral transfer and plotted SDC-4 
expression against HIV-1 transfer to assess whether there may some impact of SDC-4 
knockdown on cell-to-cell viral transfer (Figure 18). 
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Figure 18: Overview summary of SDC-4 experiments. 	
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DISCUSSION 
 
 The receptors involved in renal epithelial HIV-1 uptake have been evaluated by 
several laboratories [12, 13]. Despite the previous literature that suggests a role for HSPG 
receptors in cell-to-cell transfer, to-date, the members of this broad class of receptors 
have not been systemically assessed for their role. The purpose of this study was to 
elucidate whether members of the syndecan family may play a role in virus uptake 
mechanisms. 
 The immortalized human renal tubule epithelial cell line HK2 has previously been 
used as an in vitro system for studying HIVAN pathology [10, 13] and also used as donor 
cells in co-culture experiments to simulate cell-to-cell transfer. The modified molecular 
clone of HIV-1, Gag-iGFP, previously developed by the laboratory of Dr. Benjamin K. 
Chen and which was used in earlier work cited, was also chosen for this study for its 
validated capability in single-round infection, virus particle tracking, and quantification. 
This is due to the insertion of GFP between the matrix and capsid domains of the 
structural protein Gag, which oligomerizes at the plasma domain and facilitates infectious 
HIV-1 assembly [19, 20]. 
 Through these experiments, it was observed that native HK2 cells expressed each 
syndecan subtype at varying levels, with SDC2 being the most prevalent and SDC4 being 
expressed at lower levels. The potential for variation the knockout efficiency of guide 
RNAs for each syndecan was considered, and 5-6 targets were chosen for each syndecan 
member. It was proposed that if a given syndecan subtype were involved, varying levels 
of that syndecan member would show a correlated change in viral transfer. 
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 While previous work at our laboratory had shown a decrease in viral transmission 
when SDC-1 was blocked with monoclonal antibodies [13], there was no statistically 
relevant change in viral transfer to SDC1(-) HK2 cells. Similarly, there was no apparent 
change in viral transfer to HK2 cells that had decreased levels of expression of the other 
syndecan members (SDC2-4). 
 One caveat to consider is the phenomenon of syndecan shedding, which occurs 
through natural proteolytic processes but may also be induced by certain pathogens [15, 
16]. This turnover process may affect syndecan-mediated ligand entry as soluble 
syndecans would compete with cell-surface syndecans, thus potentially masking ligand 
endocytosis and HIV-1 entry. Another potential drawback would be compensation of 
other syndecan or HSPG molecules in each knockout line, which could potentially mask 
minute changes in cell-to-cell viral entry.  It may therefore be important to examine if the 
total HSPG expression is impacted by individual SDC knockouts and explore if 
combination knockouts may have a significant effect on viral transfer into the renal 
tubule cells.  Finally, considering that the original HK2 cell population was 
heterogeneous, it is possible that cells in one well may have varying levels of knockout 
efficiencies which could not be parsed with this current experimental setup. 
 The primary issues that surrounded the study design were the experimental 
timeline, which necessitated knockout cell lines to be in culture for at least 2-3 weeks 
before they could be used for transfer studies. While there were usually enough cells for 
transfer by day 16 post-transduction, experiments were often run at a later date due to 
availability of Jurkat cells as donors as well as other time constraints. This was not 
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expected to pose any issue with regards to cell surface expression of the syndecans as it 
remained stable for at least three weeks, with varying levels of phenotype reversion after 
30 days in culture (data not shown). 
 Another significant issue encountered was the inconsistent HIV Gag-iGFP 
transfection efficiencies of Jurkat cells, which have varied from 8 to 40% throughout the 
course of this study. It was determined that the optimal passage number for Jurkat cells 
before transfection was between 2-4, with decreasing efficiencies as cells were cultured 
for longer periods of time. However, other factors, such as the vender source of FBS, are 
also thought to be involved as transfection efficiencies continued to be inconsistent 
despite the aforementioned changes made. 
 The final limitation in this study is that the number of biological replicates in our 
viral transfer studies performed thus far do not support conclusions with robust statistical 
significance. Given the scale of these experiments, each target could easily be run only 
once if studying more than one syndecan member at a time. Considering that previous 
experiments had suggested a role for SDC-1 in viral transfer to HK2 cells, SDC1(-) lines 
were run in duplicates for transfer studies.    
 Identification of the receptors that are involved in renal epithelial viral entry may 
help to explain how the renal tubule cells play an important role in sensing viral infection 
and initiating an innate immune response that may exacerbate viral infection and local 
tissue dysfunction.  The studies will also help to explain how the renal tissue can serve as 
a viral reservoir even when plasma viral load has been sufficiently reduced [1-3].  
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Investigating the viral life cycle in renal tissue may ultimately assist in preventing the 
onset of HIVAN and further reducing AIDS-related morbidity.  
Future directions 
 Given the potential for cross-reactivity of HSPGs in HIV-1 transfer to HK2 cells, 
a future assay should consider knocking out multiple members of the syndecan and/or 
HSPG family in a given experiment. Furthermore, additional methods to assess 
knockdown, such as Western blots, can be included to account for the levels of total 
HSPGs expressed at the cell surface and exclude soluble HSPG molecules.     
 The experimental timeline can also be adjusted to provide a more efficient 
screening process. For example, multi-target siRNAs or gRNAs may be used to improve 
individual target knockout efficiencies, which would enable more targets across the 
HSPG family to be considered at a time.  
Furthermore, the transfer assay may be modified through additional staining of 
target receptors to allow for assessment of cellular-level protein expression that could be 
directly compared to viral transfer, as opposed to the current population-level expression 
levels that were obtained separately from the transfer studies. Finally, additional HSPG 
receptors have yet to be assessed for their role in cell-to-cell viral uptake into HK2 cells, 
including agrin and perlecan.  
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